Literature DB >> 23125547

Use of antifungal drugs in hematology.

Marcio Nucci1.   

Abstract

Invasive fungal disease represents a major complication in hematological patients. Antifungal agents are frequently used in hematologic patients for different purposes. In neutropenic patients, antifungal agents may be used as prophylaxis, as empiric or preemptive therapy, or to treat an invasive fungal disease that has been diagnosed. The hematologist must be familiar with the epidemiology, diagnostic tools and strategies of antifungal use, as well as the pharmacologic proprieties of the different antifungal agents. In this paper the principal antifungal agents used in hematologic patients will be discussed as will the clinical scenarios where these agents have been used.

Entities:  

Keywords:  Antifungal agents; Aspergillosis; Mycoses

Year:  2012        PMID: 23125547      PMCID: PMC3486829          DOI: 10.5581/1516-8484.20120095

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


  67 in total

1.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).

Authors:  Oliver A Cornely; Johan Maertens; Mark Bresnik; Ramin Ebrahimi; Andrew J Ullmann; Emilio Bouza; Claus Peter Heussel; Olivier Lortholary; Christina Rieger; Angelika Boehme; Mickael Aoun; Heinz-August Horst; Anne Thiebaut; Markus Ruhnke; Dietmar Reichert; Nicola Vianelli; Stefan W Krause; Eduardo Olavarria; Raoul Herbrecht
Journal:  Clin Infect Dis       Date:  2007-04-09       Impact factor: 9.079

2.  Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials.

Authors:  Marcio Nucci; Elias Anaissie; Robert F Betts; Bertrand F Dupont; Chunzhang Wu; Donald N Buell; Laura Kovanda; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial.

Authors:  K A Marr; K Seidel; M A Slavin; R A Bowden; H G Schoch; M E Flowers; L Corey; M Boeckh
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

4.  A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.

Authors:  J R Wingard; M H White; E Anaissie; J Raffalli; J Goodman; A Arrieta
Journal:  Clin Infect Dis       Date:  2000-11-07       Impact factor: 9.079

5.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

6.  Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.

Authors:  Flavio Queiroz-Telles; Eitan Berezin; Guy Leverger; Antonio Freire; Annalie van der Vyver; Tawee Chotpitayasunondh; Josip Konja; Heike Diekmann-Berndt; Sonja Koblinger; Andreas H Groll; Antonio Arrieta
Journal:  Pediatr Infect Dis J       Date:  2008-09       Impact factor: 2.129

7.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

8.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Authors:  Peter G Pappas; Coleman M F Rotstein; Robert F Betts; Marcio Nucci; Deepak Talwar; Jan J De Waele; Jose A Vazquez; Bertrand F Dupont; David L Horn; Luis Ostrosky-Zeichner; Annette C Reboli; Byungse Suh; Raghunadharao Digumarti; Chunzhang Wu; Laura L Kovanda; Leah J Arnold; Donald N Buell
Journal:  Clin Infect Dis       Date:  2007-08-29       Impact factor: 9.079

9.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

10.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.

Authors:  Kieren A Marr; Fulvio Crippa; Wendy Leisenring; Maggie Hoyle; Michael Boeckh; S Arunmozhi Balajee; W Garrett Nichols; Benjamin Musher; Lawrence Corey
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

View more
  3 in total

Review 1.  Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).

Authors:  Can Boğa; Zahit Bolaman; Seçkin Çağırgan; İhsan Karadoğan; Mehmet Ali Özcan; Fahir Özkalemkaş; Rabin Saba; Mehmet Sönmez; Esin Şenol; Hamdi Akan; Murat Akova
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

2.  D-index: A New Scoring System in Febrile Neutropenic Patients for Predicting Invasive Fungal Infections.

Authors:  Gülden Yılmaz; Belgin Coşkun; Atilla Elhan; Alpay Azap; Hamdi Akan
Journal:  Turk J Haematol       Date:  2014-05-21       Impact factor: 1.831

3.  Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.

Authors:  Song Mu; Zhiyu Tang; William Novotny; Manal Tawashi; Ta-Kai Li; Ying Ou; Srikumar Sahasranaman
Journal:  Cancer Chemother Pharmacol       Date:  2019-12-26       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.